科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose Response Evaluation Criteria in Solid Tumors Version 11 (RECIST 11) has added positron emission tomography (PET) as an optional complement for the detection of new lesions In this study, we evaluate the utility of fluorodeoxyglucose (FDG)-PET in the identification of new lesions and progressive disease not recognized on computed tomography (CT) in patients with nonsmall cell lung cancer (NSCLC) undergoing therapy
Materials and methods Seventy patients (30 female, 40 male, mean age 67 14 years, range, 39-94 years) with NSCLC underwent FDG-PET before and after chemotherapy and/or radiotherapy, whereas 69 patients underwent CT imaging Overall (OS) and progression free survivals (PFS) were calculated for RECIST 11 with CT alone, RECIST 11 with PET for the identification of new lesions, visual PET, and semiquantitative PET using a change in standardized uptake value ranging from - 15 to -50%
Results PET identified new lesions in 26 patients, resulting in 10 patients (145%) being upgraded to progressive disease The combination of CT and PET for the detection of new lesions improved the prediction of survival (OS P=0 0491 for all stages and P=0 0033 for stage IV, PFS P=0 0045 for stage IV) compared with CT imaging alone (OS P=0 1362 for all stages and P=0 1625 for stage IV, PFS P=0 0632 for stage IV) Furthermore, a change in standardized uptake value of - 35% was the most discriminative for the prediction of survival for the semiquantitative PET approach (OS P=0 0393 for all stages, P=0 0051 for stage IV, PFS P=0 0092 for stage IV) and more discriminative than the visual PET approach (OS P=0 2699 for all stages, P=0 0105 for stage IV, PFS P=0014 for stage IV)
Conclusion FDG PET is helpful in identifying new lesions in NSCLC patients, resulting in the improved assessment of therapy response with CT imaging combined with FDG-PET compared with CT imaging alone Although RECIST 11 includes FDG PET only as an optional adjunct, we recommend the implementation of PET im
- 出版日期2010-12
